VivoSeq
Other

Toxicity

176

Pipeline Programs↗

30

Active Trials↗

58

Companies Involved↗

Toxicity is a highly competitive landscape with 176 programs across 58 companies. The most active players are Castle Creek Pharmaceuticals, LLC, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Kenvue Brands. 27 therapies are approved with 27 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

22/100

Mech. Concentration

5/100

Completion Rate

81/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Castle Creek Pharmaceuticals, LLC

1 program

Phase 1I

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1 program

Phase 1K

Kenvue Brands

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 2Amgen logo

Amgen

2 programs

Phase 2T

The Korean Society of Pediatric Hematology Oncology

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical38

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Atezolizumab

Roche

Carboplatin

Avyxa

Durvalumab

AstraZeneca

Phase 119

Melphalan

Apotex Inc.

Bevacizumab

Bio-Thera Solutions

Irinotecan

Pfizer

Acetaminophen

Kenvue Brands

Polyphenon E

Louisiana State University Health Sciences Center Shreveport

Phase 265

Dapagliflozin

AstraZeneca

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Gemcitabine

Johnson & Johnson

Dexamethasone

Aspen Global Incorporated

Thalidomide

Bristol-Myers Squibb

Phase 327

Misoprostol

Pfizer

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Mitomycin C

Gynecologic Oncology Group

Midazolam

Conrado Roberto Hoffmann Filho

Cetuximab

Imclone

Approved27

Atropine

Fresenius Kabi Oncology Ltd.

Prednisone

Roxane Laboratories

Vincristine

Eli Lilly

Spironolactone

Pfizer

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Analysis

Modality Breakdown

92%

Small molecule

197 of 214 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody126%Protein / enzyme2<1%Peptide1<1%Cell therapy1<1%Vaccine1<1%

Small molecule leads; the ring shows all 214 classified programs, each share of the total. Modality classified for 100% of 224 pipeline programs.

Analysis

Trial Status

185

clinical trials

Completed90 · 49%
Unknown status41 · 22%
Recruiting19 · 10%
Terminated14 · 8%
Not yet recruiting6 · 3%
Withdrawn6 · 3%
Other9 · 5%

Clinical Trials

Trial Activity

185 trials

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05559164·60 enrolled
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
Recruiting·UUniversity of Utah·Phase 2·NCT06358677·25 enrolled
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Recruiting·ZZhejiang Cancer Hospital·Phase 3·NCT06214195·276 enrolled
Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors
Recruiting·MMasaryk Memorial Cancer Institute·N/A·NCT03751566·60 enrolled
Ofloxacin Concentration-toxicity Relationship in the Elderly
Recruiting·—·N/A·NCT04496024·110 enrolled
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
Recruiting·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT07018622·46 enrolled
L-Carnitine Protective Effect in Nephrotoxicity
Recruiting·TTanta University·Phase 2·NCT07108777·46 enrolled
Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores in Older Adults With Cancer in China
Recruiting·RRenJi Hospital·N/A·NCT06717178·322 enrolled
Oxygen Toxicity: Mechanisms in Humans
Recruiting·—·N/A·NCT05761756·62 enrolled
NBMI Treatment in Patients With Mercury Toxicity
Recruiting·EEmeraMed·Phase 2/3·NCT04183595·116 enrolled
Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation
Recruiting·UUniversity of Cincinnati·Phase 1·NCT07231588·20 enrolled
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
Recruiting·IInstituto Nacional de Cancerologia de Mexico·N/A·NCT02734069·132 enrolled
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
Recruiting·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT04807114·70 enrolled
Pantoprazole in Cisplatin Nephrotoxicity
Recruiting·—·Phase 3·NCT04217512·60 enrolled
Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
Recruiting·—·N/A·NCT06765252·80 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)